靶向OX40和OX40L单克隆抗体治疗特应性皮炎的研究进展OA

Atopic dermatitis(AD)is a chronic in-flammatory skin disease characterized by a T helper cells(th)2-dominant immune response coupled with multifactorial immune dysregulation involving Th1,Th17,and Th22 pathways.Current therapeutic approaches confront significant clinical challenges,including suboptimal treatment responses in sub-sets of patients,safety risks associated with pro-longed pharmacotherapy,and compromised pa-tient adherence.Emerging evidence demonstrates that the OX40-OX40L signaling pathway orches-trates sustained immunoinflammatory responses through its regulatory role in antigen-presenting cell-T cell interactions.Monoclonal antibodies tar-geting this pathway effectively inhibit pathological immune activation,demonstrating dual clinical ben-efits of ameliorating cutaneous lesions and main-taining durable remission after treatment cessation.This review systematically elucidates the mechanis-tic involvement of the OX40-OX40L axis in AD pathogenesis and provides a comprehensive analy-sis of clinical trial advancements in anti-OX40/OX40L monoclonal antibody therapeutics.